Compare · MASI vs NDRA
MASI vs NDRA
Side-by-side comparison of Masimo Corporation (MASI) and ENDRA Life Sciences Inc. (NDRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASI and NDRA operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.36B, about 1496.7x NDRA ($6.3M).
- Over the past year, MASI is up 9.1% and NDRA is up 40.6% - NDRA leads by 31.4 points.
- NDRA has been more active in the news (6 items in the past 4 weeks vs 2 for MASI).
- MASI has more recent analyst coverage (24 ratings vs 0 for NDRA).
- Company
- Masimo Corporation
- ENDRA Life Sciences Inc.
- Price
- $178.78+0.04%
- $4.99-9.11%
- Market cap
- $9.36B
- $6.3M
- 1M return
- +0.32%
- +2.46%
- 1Y return
- +9.13%
- +40.56%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2017
- News (4w)
- 2
- 6
- Recent ratings
- 24
- 0
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Latest MASI
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher
- Amendment: SEC Form 10-K/A filed by Masimo Corporation
Latest NDRA
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form RW filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form S-8 filed by ENDRA Life Sciences Inc.
- SEC Form 10-Q filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update